Nanobodies or single domain antibodies are the smallest antigen-recognizing parts of the heavy-chain-antibodies found in camels and other members of the Camelidae. They are known to be very stable, specific and non-immunogenic and are therefore promising candidates to be developed as an anti-polioviral drug. We previously reported about a set of nanobodies that show an in vitro neutralizing activity on poliovirus type 1. Due to the generation of neutralization-escape virus mutants during treatment of infected HeLa cells with these nanobodies, a combination therapy with two or more nanobodies targeting different epitopes would be essential to overcome the induction of drug-resistant virus. Nanobodies are encoded by single-genes and can be easily tailored in different formats like bispecific (two different nanobodies) or bivalent (two identical nanobodies) constructs. These constructs are expected to show a higher avidity for their antigen as they possess two paratopes. Here, we compare the influence on the in vitro neutralizing activity of five different protein-linkers, differing from each other in both length and flexibility, by making constructs of nanobodies PVSP29F and PVSP6A (known to target two different epitopes).
Original languageEnglish
Title of host publicationEUROPIC 2012: XVII Meeting of the European Study Group on the Molecular Biology of Picornaviruses, St. Raphael, France (June 3-7)
Publication statusPublished - 2012
EventUnknown -
Duration: 1 Jan 2012 → …

Publication series

NameEUROPIC 2012: XVII Meeting of the European Study Group on the Molecular Biology of Picornaviruses, St. Raphael, France (June 3-7)

Conference

ConferenceUnknown
Period1/01/12 → …

    Research areas

  • poliovirus, nanobody, VHH

ID: 2209866